Commission proposes JTI for innovative medicines


Brussels – The European Commission and the European Federation of Pharmaceutical Industry Associations, EFPIA, have launched a proposal to establish the European Union’s first Joint Technology Initiative on Innovative Medicines, IMI. According to the plan, which must now be adopted by the EU Council and the European Parliament, the Commission will invest a1 billion into IMI to streamline the drug development process over the next 7 years.
The investment will go entirely to small and medium-sized enterprises (SMEs) and universities for research that can be employed by the pharmaceutical sector. Another a1 billion will be invested by the pharmaceutical industry.
Projects will involve biomarker screening and in-vitro-, in-vivo and in-silico models to improve the prediction of drug safety and efficacy. If approved during the Portuguese EU presidency, it would be the first time that competing biopharmaceutical companies will work closely together with the aim of developing tools that improve the predictability of safety and efficacy of drug candidates. The first calls could be announced in 2008 at the earliest, according to an EFPIA spokesman.

Politics / Law, BeNeLuxBelgiumNetherlandsLuxembourg


Although the percentage of land devoted to growing GM crops continues to expand globally, the speed of that expansion has slowed for the fourth consecutive year. Is market saturation for herbicide-tolerant and insect-resistant...

Clinical Trial


Glasgow – British biotech company ReNeuron Group plc and a team of doctors in Scotland have won final approval to start a pioneering clinical trial to assess whether a novel stem-cell therapy can help patients disabled by stroke....

Tech Review


Given the recent increases in the capacity of next-generation sequencing systems from companies like Applied Biosystems, Roche, and Complete Genomics, the integration and analysis of genome, epigenome, transcriptome, and proteome...

Tech Review


Tumour cells change their genetic expression pattern as they progress to states of increasing malignancy, and investigations at the DNA and RNA levels alone do not provide all the information resulting from the translation and...

Politics / Law


Manila – Global acreage of genetically engineered crops reached 134 million hectares (ha) in the last year, according to the annual statistics of the ISAAA (more). Although this is an increase of 7.1% compared to 2008 figures,...

Clinical Trial


Belgian Galapagos NV’s (Mechelen) experimental inhibitor GLPG0259 of protein kinase MAPKAPK5 has shown a good safety profile in a Phase I study, the company announced in mid-February. Galapagos also said the oral small molecule...

Politics / Law


Brussels – In the last few weeks, BASF officials have been wondering why anti-GMO groups had launched a new campaign against the genetically modified potato Amflora, which is pending for EU approval. On Monday, it seems they have...



Europe is to receive a new Super Commissioner for biotech, as well as the largest budget for research the bloc has ever granted. Even before the start of hearings considering the 26 Commission nominees that began in mid-January,...

Displaying results 331 to 340 out of 1982

< Previous 331-340 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • BASILEA133.60 CHF4.70%
  • WILEX4.20 EUR3.45%


  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%


  • 4SC4.65 EUR257.7%
  • SYNGENTA422.00 CHF28.3%
  • SARTORIUS169.65 EUR18.6%


  • CYTOS0.63 CHF-37.6%
  • MEDIGENE8.58 EUR-33.2%
  • CO.DON2.89 EUR-8.3%


  • WILEX4.20 EUR418.5%
  • CYTOS0.63 CHF350.0%
  • 4SC4.65 EUR322.7%


  • MOLOGEN4.92 EUR-54.4%
  • BIOFRONTERA2.30 EUR-24.1%
  • CO.DON2.89 EUR-21.3%

No liability assumed, Date: 24.05.2015

Current issue

All issues